Literature DB >> 31197034

The chaperone SmgGDS-607 has a dual role, both activating and inhibiting farnesylation of small GTPases.

Desirée García-Torres1, Carol A Fierke2.   

Abstract

Ras family small GTPases undergo prenylation (such as farnesylation) for proper localization to the plasma membrane, where they can initiate oncogenic signaling pathways. Small GTP-binding protein GDP-dissociation stimulator (SmgGDS) proteins are chaperones that bind and traffic small GTPases, although their exact cellular function is unknown. Initially, SmgGDS proteins were classified as guanine nucleotide exchange factors, but recent findings suggest that SmgGDS proteins also regulate prenylation of small GTPases in vivo in a substrate-selective manner. SmgGDS-607 recognizes the polybasic region and the CAAX box of several small GTPases and inhibits prenylation by impeding their entry into the geranylgeranylation pathway. Here, using recombinant and purified enzymes for prenylation and protein-binding assays, we demonstrate that SmgGDS-607 differentially regulates farnesylation of several small GTPases. SmgGDS-607 inhibited farnesylation of some proteins, such as DiRas1, by sequestering the protein and limiting modification catalyzed by protein farnesyltransferase (FTase). We found that the competitive binding affinities of the small GTPase for SmgGDS-607 and FTase dictate the extent of this inhibition. Additionally, we discovered that SmgGDS-607 increases the rate of farnesylation of HRas by enhancing product release from FTase. Our work indicates that SmgGDS-607 binds to a broad range of small GTPases and does not require a PBR for recognition. Together, these results provide mechanistic insight into SmgGDS-607-mediated regulation of farnesylation of small GTPases and suggest that SmgGDS-607 has multiple modes of substrate recognition.
© 2019 García-Torres and Fierke.

Entities:  

Keywords:  GTPase Kras (KRAS); Ras protein; cancer; cell signaling; enzyme kinetics; post-translational modification (PTM); protein farnesylation; protein prenylation; small GTP-binding protein GDP-dissociation stimulator (SmgGDS); small GTPase

Mesh:

Substances:

Year:  2019        PMID: 31197034      PMCID: PMC6682747          DOI: 10.1074/jbc.RA119.007438

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Novel mechanism of the co-regulation of nuclear transport of SmgGDS and Rac1.

Authors:  Cathy Cole Lanning; Rebecca Ruiz-Velasco; Carol L Williams
Journal:  J Biol Chem       Date:  2003-01-27       Impact factor: 5.157

2.  Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents.

Authors:  S Jane deSolms; Terrence M Ciccarone; Suzanne C MacTough; Anthony W Shaw; Carolyn A Buser; Michelle Ellis-Hutchings; Christine Fernandes; Kelly A Hamilton; Hans E Huber; Nancy E Kohl; Robert B Lobell; Ronald G Robinson; Nancy N Tsou; Eileen S Walsh; Samuel L Graham; Lorena S Beese; Jeffrey S Taylor
Journal:  J Med Chem       Date:  2003-07-03       Impact factor: 7.446

3.  Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity.

Authors:  T Scott Reid; Kimberly L Terry; Patrick J Casey; Lorena S Beese
Journal:  J Mol Biol       Date:  2004-10-15       Impact factor: 5.469

4.  Unique in vivo associations with SmgGDS and RhoGDI and different guanine nucleotide exchange activities exhibited by RhoA, dominant negative RhoA(Asn-19), and activated RhoA(Val-14).

Authors:  D Strassheim; R A Porter; S H Phelps; C L Williams
Journal:  J Biol Chem       Date:  2000-03-10       Impact factor: 5.157

5.  Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.

Authors:  R B Lobell; C A Omer; M T Abrams; H G Bhimnathwala; M J Brucker; C A Buser; J P Davide; S J deSolms; C J Dinsmore; M S Ellis-Hutchings; A M Kral; D Liu; W C Lumma; S V Machotka; E Rands; T M Williams; S L Graham; G D Hartman; A I Oliff; D C Heimbrook; N E Kohl
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

6.  The basis for K-Ras4B binding specificity to protein farnesyltransferase revealed by 2 A resolution ternary complex structures.

Authors:  S B Long; P J Casey; L S Beese
Journal:  Structure       Date:  2000-02-15       Impact factor: 5.006

7.  High-level expression, purification, kinetic characterization and crystallization of protein farnesyltransferase beta-subunit C-terminal mutants.

Authors:  Z Wu; M Demma; C L Strickland; R Syto; H V Le; W T Windsor; P C Weber
Journal:  Protein Eng       Date:  1999-04

8.  SmgGDS displays differential binding and exchange activity towards different Ras isoforms.

Authors:  Haris G Vikis; Scott Stewart; Kun-Liang Guan
Journal:  Oncogene       Date:  2002-04-04       Impact factor: 9.867

9.  Rig is a novel Ras-related protein and potential neural tumor suppressor.

Authors:  Chad A Ellis; Michele D Vos; Heather Howell; Teresa Vallecorsa; Daniel W Fults; Geoffrey J Clark
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-09       Impact factor: 11.205

10.  High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.

Authors:  James J Fiordalisi; Ronald L Johnson; Carolyn A Weinbaum; Kaoru Sakabe; Zhui Chen; Patrick J Casey; Adrienne D Cox
Journal:  J Biol Chem       Date:  2003-07-25       Impact factor: 5.157

View more
  6 in total

1.  Splice switching an oncogenic ratio of SmgGDS isoforms as a strategy to diminish malignancy.

Authors:  Anthony C Brandt; Lisa McNally; Ellen L Lorimer; Bethany Unger; Olivia J Koehn; Kiall F Suazo; Lisa Rein; Aniko Szabo; Shirng-Wern Tsaih; Mark D Distefano; Michael J Flister; Frank Rigo; Mark T McNally; Carol L Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-04       Impact factor: 11.205

Review 2.  Post-translational modification of RAS proteins.

Authors:  Sharon L Campbell; Mark R Philips
Journal:  Curr Opin Struct Biol       Date:  2021-08-06       Impact factor: 6.809

3.  Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities.

Authors:  Marcus R Kelly; Kaja Kostyrko; Kyuho Han; Nancie A Mooney; Edwin E Jeng; Kaitlyn Spees; Phuong T Dinh; Keene L Abbott; Dana M Gwinn; E Alejandro Sweet-Cordero; Michael C Bassik; Peter K Jackson
Journal:  Cancer Discov       Date:  2020-07-29       Impact factor: 38.272

Review 4.  SmgGDS: An Emerging Master Regulator of Prenylation and Trafficking by Small GTPases in the Ras and Rho Families.

Authors:  Anthony C Brandt; Olivia J Koehn; Carol L Williams
Journal:  Front Mol Biosci       Date:  2021-06-16

Review 5.  Post-translational modification of KRAS: potential targets for cancer therapy.

Authors:  Wei-Hua Wang; Tao Yuan; Mei-Jia Qian; Fang-Jie Yan; Liu Yang; Qiao-Jun He; Bo Yang; Jin-Jian Lu; Hong Zhu
Journal:  Acta Pharmacol Sin       Date:  2020-10-21       Impact factor: 7.169

6.  Chromosomal translocation-derived aberrant Rab22a drives metastasis of osteosarcoma.

Authors:  Dan Liao; Li Zhong; Junqiang Yin; Cuiling Zeng; Xin Wang; Xingchuan Huang; Jinna Chen; Hong Zhang; Ruhua Zhang; Xin-Yuan Guan; Xintao Shuai; Jianhua Sui; Song Gao; Wuguo Deng; Yi-Xin Zeng; Jing-Nan Shen; Jian Chen; Tiebang Kang
Journal:  Nat Cell Biol       Date:  2020-06-01       Impact factor: 28.213

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.